Scilex Holding Company (SCLX) |
|
7.82 0.45 (6.11%)
|
03-24 16:00 |
|
Open: |
7.28 |
Pre. Close: |
7.37 |
|
High:
|
7.83 |
Low:
|
7.05 |
|
Volume:
|
141,450 |
Market Cap:
|
1,140(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:39 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 9.65 One year: 11.15 |
| Support: |
Support1: 6.19 Support2: 5.15 |
| Resistance: |
Resistance1: 8.27 Resistance2: 9.55 |
| Pivot: |
7.87  |
| Moving Average: |
MA(5): 7.8 MA(20): 8.11
MA(100): 7.02 MA(250): 8.97 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 42.6 %D(3): 47 |
| RSI: |
RSI(14): 49 |
| 52-week: |
High: 11.68 Low: 2.86 |
| Average Vol(K): |
3-Month: 382 (K) 10-Days: 191 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SCLX ] has closed above bottom band by 47.3%. Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.83 - 7.87 |
7.87 - 7.91 |
|
Low:
|
6.97 - 7 |
7 - 7.04 |
|
Close:
|
7.76 - 7.82 |
7.82 - 7.88 |
|
Company Description |
|
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc. |
Headline News |
Tue, 21 Mar 2023
Scilex Holding Company Announces Financing of up to $25 Million ... - GlobeNewswire
Thu, 16 Mar 2023
SORRENTO THERAPEUTICS, INC. Management's Discussion and ... - Marketscreener.com
Thu, 09 Mar 2023
Scilex Holding Full Year 2022 Earnings: US$0.17 loss per share (vs US$0.45 loss in FY 2021) - Simply Wall St
Wed, 08 Mar 2023
Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment - Yahoo Finance
Thu, 02 Mar 2023
Scilex Holding (NASDAQ:SCLX) adds US$65m to market cap in the past 7 days, though investors from a year ago are still down 16% - Simply Wall St
Mon, 27 Feb 2023
Scilex Holding Company (SCLX) Announces Commercial Launch of ... - StreetInsider.com
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
146 (M) |
| Shares Float |
86 (M) |
|
% Held by Insiders
|
43 (%) |
|
% Held by Institutions
|
7.4 (%) |
|
Shares Short
|
708 (K) |
|
Shares Short P.Month
|
566 (K) |
Stock Financials |
|
EPS
|
-0.18 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.25 |
|
Profit Margin (%)
|
-61.5 |
|
Operating Margin (%)
|
-133.2 |
|
Return on Assets (ttm)
|
-38.5 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
44.2 |
|
Gross Profit (p.s.)
|
0.18 |
|
Sales Per Share
|
0.26 |
|
EBITDA (p.s.)
|
-0.33 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-21 (M) |
|
Levered Free Cash Flow
|
-103 (M) |
Stock Valuations |
|
PE Ratio
|
-46 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
30.07 |
|
Price to Sales
|
29.98 |
|
Price to Cash Flow
|
-53.64 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
